The roster of radiopharmaceuticals players in the Indianapolis area has surged in the past few years to include some of the world’s leading pharmaceutical companies, attracted by the potential for significant growth.
Primary Record allows families and other caregivers to organize and share medical information with one another and with doctors from their computer or phone.
Lilly’s newest obesity and diabetes medicines, widely known as GLP-1 drugs, are drawing rave reviews from doctors, researchers and patients for their ability to safely and effectively control blood sugar and take off weight.
The Carmel medical group is gaining a reputation as a training and education center. It holds courses for high school and college students in anatomy as well as surgeons going out on their own after residencies and fellowships.
In the past five years, the nation’s largest Catholic health system has unloaded more than a dozen hospitals across the country, from New York to Alabama, as it restructures amid a growing tide of red ink.
A Feb. 21 cyberattack against a Nashville, Tennessee-based medical-billing clearinghouse sent shock waves across Indiana’s health care system.
The Greenfield-based maker of animal vaccines, antibiotics and other health products said that as part of the agreement with Ancora Holding Inc., it will appoint two new independent directors supported by the investment firm to its board.
Some local workplaces’ plans include everything from shifting delivery and staffing schedules to paring back operations to working remotely—or even taking the day off.
Ancora Holdings Inc. is pushing for a shakeup in leadership at he Greenfield-based animal health company, which it accuses of delivering poor margins, sluggish product commercialization, negative shareholder returns and poor governance policies.
In the past 52 weeks, shares have set new records almost every week, due to investor eagerness over the company’s new drugs for obesity and diabetes, two health conditions that plague America, along with other drugs in the pipeline.
The Indiana Donor Network, which serves 85 of Indiana’s 92 counties, is booming with a record number of registered donors and transplanted organs.
In recent weeks, the Indianapolis-based philanthropy has been unveiling a flurry of gifts at the $100 million level or higher.
The Indianapolis based drugmaker posted net income of $2.19 billion for the quarter. Excluding nonrecurring items, adjusted earnings per share of $2.49 beat the FactSet consensus of $2.30.
Thirty-four Indiana companies landed $287 million in venture capital in 2023 to help finance a wide array of technologies, from medical isotopes to stem-cell therapies, according to BioCrossroads, an Indianapolis-based group that promotes and invests in the state’s life sciences sector and tracks the funding.
Cook Biotech employs 275 people, all of whom will transition to RTI Surgical once the deal closes.
Indiana’s pharmaceutical and medical device sectors, long touted as major contributors to the state’s economy, are starting to lag the nation in growth and market share and will require a focused effort to stay competitive, according to a new report released Monday.
David Ricks led Eli Lilly and Co. to milestone after milestone in 2023, with a slew of product launches for diseases from obesity to inflammatory bowel disease. And when Lilly wasn’t scoring wins in the laboratory, it was issuing a series of head-turning announcements,
It was a busy year for the Indiana life sciences community, with a flurry of billion-dollar deals, major announcements, and a few setbacks. Here we present the top 10 stories of 2023—the good, the bad and the ugly—about an industry that is often hailed as a key driver of Indiana’s economy.
The investment in Sudo Biosciences, a three-year-old Carmel biotech, is one of the largest in recent years for an Indiana-based science startup, a signal that investors are attracted by its work on a class of drugs to treat autoimmune and inflammatory diseases.
Results of a clinical trial for Point Biopharma’s lead compound fell short of analysts’ expectations, and that development is likely to pressure its investors to decide whether to agree to sell the company to Eli Lilly and Co. for $1.4 billion.
